AstraZeneca and partner Merck & Co look set to have a much narrower label for their PARP inhibitor Lynparza in prostate cancer than they were hoping for in the US. The FDA’s Oncologic Drugs ...

AstraZeneca (NASDAQ:AZN) and Merck (NYSE:MRK) said long-term data from a Phase 3 study showed that 87.5% of patients treated with their breast cancer drug Lynparza were still alive six years later ...

Also approved to treat ovarian, prostate and pancreatic cancer, Lynparza brought in $2.75 billion in sales for AZ last year, a rise of around 25%, while Merck booked just under $1 billion from the ...

Aliya Omer, VP, US franchise head, breast cancer, AstraZeneca, discusses Lynparza’s role in reducing the risk of invasive disease recurrence or death in HR-positive breast cancer patients. In December ...